Aimei Health Extends SPAC Deadline, Issues $34,330.96 Promissory Note

What Happened Aimei Health Technology Co., Ltd. (filed Aug 6, 2026) announced it deposited $34,330.96 into its public trust to extend the deadline to complete its SPAC business combination from August 6, 2026 to September 6, 2026. This is the 21st monthly extension permitted under the Company’s Amended and Restated Articles of Association. To fund the extension payment, the Company issued an unsecured, non‑interest bearing promissory note dated August 6, 2026, in the principal amount of $34,330.96 to Aimei Health Ltd (the Payee).

Key Details

• Extension payment: $34,330.96 deposited into the public shareholder trust to extend the Termination Date from Aug 6, 2026 to Sep 6, 2026.
• Extension formula: the deposited amount represents the lesser of (i) $80,000 for all outstanding public shares or (ii) $0.033 per outstanding public share per month.
• Promissory Note: $34,330.96 principal, unsecured, bears no interest, payable when the Company consummates its business combination with United Hydrogen.
• Conversion right: the Payee may convert the Promissory Note, in whole or in part, into private units at $10.00 per unit (one ordinary share plus a right to receive 1/5 of one ordinary share), by giving written notice at least two business days before closing of the business combination.

Why It Matters The filing extends the SPAC deadline by one month, giving the Company more time to close its planned business combination with United Hydrogen. The extension fee was funded via a related‑party promissory note rather than from the public trust funds; that note is a direct financial obligation of the Company and becomes payable upon closing the business combination. If converted, the note would create private units at $10 each, which could affect the post‑combination ownership mix. Retail investors should note the extended timeline and the existence of a convertible obligation when assessing potential dilution and the Company’s path to closing the merger.